| Primary |
| Acute Myeloid Leukaemia |
23.4% |
| Product Used For Unknown Indication |
20.0% |
| Acute Lymphocytic Leukaemia |
16.5% |
| Prophylaxis |
8.6% |
| Drug Use For Unknown Indication |
4.0% |
| Pain |
3.2% |
| Nausea |
2.9% |
| Myeloid Leukaemia |
2.8% |
| Acute Lymphocytic Leukaemia Recurrent |
2.5% |
| Sedation |
2.4% |
| Acute Leukaemia |
2.3% |
| Myelodysplastic Syndrome |
1.7% |
| Premedication |
1.7% |
| Bone Marrow Conditioning Regimen |
1.4% |
| Pyrexia |
1.4% |
| Infection |
1.2% |
| Dry Skin |
1.1% |
| Non-hodgkin's Lymphoma |
1.0% |
| Anti-infective Therapy |
0.9% |
| Acute Myeloid Leukaemia Recurrent |
0.9% |
|
| Sepsis |
12.9% |
| Vomiting |
8.7% |
| Death |
7.1% |
| Septic Shock |
6.6% |
| White Blood Cell Count Decreased |
5.8% |
| Pneumonia |
5.4% |
| Renal Failure |
5.4% |
| Thrombocytopenia |
5.0% |
| Pancytopenia |
4.6% |
| Tachycardia |
4.6% |
| Staphylococcal Infection |
4.1% |
| Febrile Neutropenia |
3.7% |
| Rash |
3.7% |
| Syncope |
3.7% |
| Pyrexia |
3.3% |
| Renal Failure Acute |
3.3% |
| Therapy Non-responder |
3.3% |
| Lipase Increased |
2.9% |
| Neutropenia |
2.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
2.9% |
|
| Secondary |
| Acute Myeloid Leukaemia |
26.2% |
| Product Used For Unknown Indication |
15.2% |
| Acute Lymphocytic Leukaemia |
14.0% |
| Bone Marrow Conditioning Regimen |
6.1% |
| Myelodysplastic Syndrome |
6.1% |
| Prophylaxis Against Graft Versus Host Disease |
4.0% |
| Prophylaxis |
3.2% |
| Acute Lymphocytic Leukaemia Recurrent |
3.0% |
| Antibiotic Prophylaxis |
2.9% |
| Chemotherapy |
2.8% |
| Myeloid Leukaemia |
2.4% |
| Acute Leukaemia |
2.2% |
| Antifungal Prophylaxis |
2.2% |
| Stem Cell Transplant |
1.9% |
| Nausea |
1.6% |
| Febrile Neutropenia |
1.5% |
| Antiviral Prophylaxis |
1.4% |
| Hypertension |
1.2% |
| Leukaemia Recurrent |
1.1% |
| Blood Product Transfusion Dependent |
0.9% |
|
| Sepsis |
10.7% |
| Vomiting |
9.1% |
| Septic Shock |
7.5% |
| Death |
7.0% |
| Pyrexia |
6.4% |
| Cerebral Haemorrhage |
5.3% |
| Neutropenic Sepsis |
5.3% |
| Tachycardia |
5.3% |
| Neutropenia |
4.3% |
| Toxicity To Various Agents |
4.3% |
| Renal Failure |
3.7% |
| Renal Failure Acute |
3.7% |
| Respiratory Failure |
3.7% |
| Thrombocytopenia |
3.7% |
| Venoocclusive Liver Disease |
3.7% |
| Mucosal Inflammation |
3.2% |
| Nephropathy Toxic |
3.2% |
| Pseudomonal Sepsis |
3.2% |
| Renal Impairment |
3.2% |
| Staphylococcal Sepsis |
3.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
35.1% |
| Drug Use For Unknown Indication |
18.2% |
| Bone Marrow Conditioning Regimen |
12.1% |
| Acute Myeloid Leukaemia |
5.9% |
| Stem Cell Transplant |
5.4% |
| Acute Lymphocytic Leukaemia |
4.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.8% |
| Immunosuppression |
2.6% |
| Prophylaxis |
2.3% |
| Acute Lymphocytic Leukaemia Recurrent |
2.1% |
| Non-hodgkin's Lymphoma |
2.1% |
| Acute Graft Versus Host Disease |
1.0% |
| Surgical Preconditioning |
1.0% |
| Antibiotic Prophylaxis |
0.8% |
| Antifungal Prophylaxis |
0.8% |
| B Precursor Type Acute Leukemia |
0.8% |
| Bone Marrow Transplant |
0.8% |
| Nausea |
0.8% |
| Neutropenia |
0.8% |
| Pain |
0.8% |
|
| Hypoxia |
10.5% |
| Pneumonia |
10.5% |
| Drug Ineffective |
7.9% |
| Drug Interaction |
7.9% |
| Pseudomonas Infection |
7.9% |
| Death |
5.3% |
| Disease Progression |
5.3% |
| Encephalitis |
5.3% |
| Hepatotoxicity |
5.3% |
| Multi-organ Failure |
5.3% |
| Neuropathy Peripheral |
5.3% |
| Acute Graft Versus Host Disease In Skin |
2.6% |
| Acute Myeloid Leukaemia |
2.6% |
| Aspergillosis |
2.6% |
| Cardiac Failure |
2.6% |
| Cystitis Haemorrhagic |
2.6% |
| Epistaxis |
2.6% |
| Hypersensitivity |
2.6% |
| Hyponatraemia |
2.6% |
| Infection |
2.6% |
|
| Interacting |
| Product Used For Unknown Indication |
28.1% |
| Prophylaxis |
21.1% |
| Acute Lymphocytic Leukaemia |
10.5% |
| Pain |
7.0% |
| Pyrexia |
7.0% |
| Vomiting |
7.0% |
| Analgesic Therapy |
4.1% |
| Hypertension |
3.5% |
| Nausea |
3.5% |
| Neuralgia |
3.5% |
| Pain Management |
3.5% |
| Drug Use For Unknown Indication |
1.2% |
|
| Tumour Lysis Syndrome |
85.7% |
| Agranulocytosis |
14.3% |
|
